Dolutegravir Regimen Superior to Standard Combination ART for HIV

hivReplicationCycleAn HIV treatment regimen of dolutegravir plus abacavir-lamivudine is superior to a currently recommended combination pill, according to a phase III trial published in the New England Journal of Medicine.

In the manufacturer-conducted SINGLE study, roughly 850 treatment-naive patients were randomized to dolutegravir (an integrase inhibitor) plus abacavir-lamivudine or to efavirenz-tenofovir disoproxil fumarate-emtricitabine (EFV/TDF/FTC). After 48 weeks of treatment, the dolutegravir group had a higher percentage of patients with HIV-1 RNA levels under 50 copies per milliliter (88% vs. 81%). The number of adverse events was lower in the dolutegravir group.

In his blog HIV and ID Observations, Paul Sax writes: “Up until the SINGLE study, one could argue that EFV-based treatments — especially TDF/FTC/EFV — represented the gold standard against which all other regimens must compete. Has that now changed? I think it has.”

Abstract from the NEJM:

See also:


Nights of Talent

It is easy for one to marvel at the grandeur of New York City, the world-class plays of Broadway, the gourmet restaurants of 57th Street, the dazzling spectacle that is Times Square. However, few may realize that an incredible scene lurks just beneath the surface of what is the common New York experience. I’m speaking, of course, of the local art scene.

Much to my benefit, I happen to have befriended one such artist a number of years ago and had the privilege to attend an exhibition of her and other artist’s work. The pieces I had the privilege to see that night were extraordinary. Continue reading

%d bloggers like this: